Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NextFoods is a functional food and beverage company that develops and markets probiotic products under the GoodBelly brand. The company focuses on the integration of biotechnology and nutrition, specifically utilizing the well-documented probiotic strain Lactobacillus plantarum 299v (Lp299v) to support digestive and immune health. Founded by industry veterans from Silk Soymilk, NextFoods emphasizes clinical validation for its product offerings, which include probiotic juices, shots, and supplements. The company's products are designed to survive the stomach's acidic environment to effectively colonize the intestinal tract. NextFoods was acquired by Danone Manifesto Ventures in 2020, facilitating its expansion within the global health and wellness market. Through its partnership with Probi AB, the company continues to leverage scientific research to address gastrointestinal conditions like Irritable Bowel Syndrome.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NextFoods.